Navigation Links
Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) announced today that Lewis H. Bender, Chief Executive Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at 11:35 am EST. The conference will be held at the New York Palace Hotel in New York.

A live audio webcast of the presentation will be available on the Events section of the Interleukin Genetics website, http://www.ilgenetics.com/content/about-interleukin/events.jsp. A replay of the presentation will be available on the Company's website for 14 days following the presentation.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin-12 indicates survival prospects for melanoma patients
2. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
3. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
4. T cell immunity enhanced by timing of interleukin-7 therapy
5. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
6. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
7. DNA Direct and Iverson Genetics Announce Partnership to Provide Personalized Patient Reports for Warfarin Dosing Test Results
8. Genetics, Environment Shape Sexual Behavior
9. Homosexual behavior due to genetics and environmental factors
10. 2008 Gruber Genetics Prize awarded to Allan Spradling of Carnegie Institution
11. 6 Nobel Prize Winners at International Congress of Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers ... and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 ... SHOT Show is the shooting, hunting and outdoor trade show and conference for ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, ... complimentary consultations and financing for orthodontics for a limited time. Complimentary for a ... about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date ... http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and advocate ... syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 - First major agreements signed with ... expected to grow by a CAGR of approximately 6-9% between ... company which operates globally across a number of sectors, announces that ... notable successes and is well-positioned for further expansion within the rapidly ... ...
(Date:1/17/2017)... , Jan. 17, 2017  Allergan Plc (NYSE: ... from Venus II, the second of two pivotal phase III ... in women with abnormal bleeding due to uterine fibroids.  A ... the second half of 2017. "We are pleased ... and safety profile of ulipristal acetate as shown in our ...
(Date:1/16/2017)... Research and Markets has announced the addition of the "Global ... ... drugs market to grow at a CAGR of 9.19% during the ... and the growth prospects of the global multiple myeloma drugs market ... revenue generated from the sales of branded and generic drugs used ...
Breaking Medicine Technology: